AACR Annual Meeting 2023 AACR 2023: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable NSCLC
Gastrointestinal Cancers BREAKWATER: Analysis of first-line encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant metastatic colorectal cancer
Genitourinary Cancers Radiopharmaceuticals for Treatment of Metastatic Castration-Resistant Prostate Cancer
